Two-year XTEND trial data shows proactive aflibercept led to meaningful functional and anatomic improvements that were maintained across the study period.
Results of the 76-week trial suggest that a treat-and-extend aflibercept regimen yields similar functional and anatomic outcomes as fixed dosing every 8 weeks among patients with nAMD.
Anatomic and visual improvements with high-dose aflibercept in CANDELA indicate a potential therapeutic benefit over aflibercept 2 mg, despite not achieving statistical significance.